Literature DB >> 9744355

Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability.

A Bhatnagar1, P R Vezza, J A Bryan, F B Atkins, H A Ziessman.   

Abstract

UNLABELLED: The purpose of this study was to evaluate the effect of P-glycoprotein (P-gp) levels, predominant histology and tumor size on the detectability of parathyroid adenomas with 99mTc-sestamibi scans. Although previous studies have shown that positivity correlates with tumor size, false-negative studies have been reported with large tumors and true-positives reported with very small tumors. Recent investigations have reported rapid washout of sestamibi in malignant tumors because of high levels of P-gp, similar to that seen with multidrug chemotherapy resistance. Therefore, we postulated that this mechanism might account for false-negative studies in parathyroid tumors. Preliminary reports have suggested that the predominant histological subtype influences positivity on 99mTc-sestamibi parathyroid scans.
METHODS: We studied 25 patients with surgically confirmed parathyroid adenomas with 99mTc-sestamibi parathyroid scans. The results of the imaging study were correlated with tissue P-gp levels, predominant histological subtype and size of the surgically removed glands.
RESULTS: There were 21 true-positive and 4 false-negative results. The size of the adenomas ranged from 0.12 to 8.64 ml. We found no correlation between the results of the dual-phase 99mTc-sestamibi study and either the predominant cell type or the level of P-gp. Positivity did correlate with the size of the adenoma (p=0.73, p < 0.0001). We cannot exclude the possibility that P-gp and cell type may still play a role in individual cases, but we suspect that other yet to be determined factors may influence 99mTc-sestamibi detectability in addition to tumor size.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744355

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

1.  Negative imaging studies for primary hyperparathyroidism are unavoidable: correlation of sestamibi and high-resolution ultrasound scanning with histological analysis in 150 patients.

Authors:  Radu Mihai; Fergus Gleeson; Ian D Buley; Derek E Roskell; Gregory P Sadler
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

2.  Scintigraphic techniques in primary hyperparathyroidism: from pre-operative localisation to intra-operative imaging.

Authors:  Domenico Rubello; Milton D Gross; Giuliano Mariani; Adil AL-Nahhas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-03-10       Impact factor: 10.057

3.  Dual-phase 99mTc-MIBI imaging and the expressions of P-gp, GST-π, and MRP1 in hyperparathyroidism.

Authors:  Jianjun Xue; Yan Liu; Danrong Yang; Yan Yu; Qianqian Geng; Ting Ji; Lulu Yang; Qi Wang; Yuanbo Wang; Xueni Lu; Aimin Yang
Journal:  Nucl Med Commun       Date:  2017-10       Impact factor: 1.690

4.  Absent 99mTc-MIBI Uptake in the Thyroid Gland during Early Phase of Parathyroid Scintigraphy in Patients with Primary and Secondary Hyperparathyroidism.

Authors:  Anamarija Jovanovska; Bojana Stoilovska; Magdalena Mileva; Daniela Miladinova; Venjamin Majstorov; Ana Ugrinska
Journal:  Open Access Maced J Med Sci       Date:  2018-05-10

5.  Radioactive Parathyroid Adenomas on Sestamibi Scans: Low Parathyroid Hormone Secretory Potential and Large Volume.

Authors:  Sung Hye Kong; Jung Hee Kim; Sang Wan Kim; Chan Soo Shin
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-06

6.  Parathyroid adenoma Localization.

Authors:  Shirzad Nasiri; Ahmadreza Soroush; Amir Pejman Hashemi; Anushiravan Hedayat; Kianoush Donboli; Farhad Mehrkhani
Journal:  Med J Islam Repub Iran       Date:  2012-08

7.  Parathyroid adenoma detected with 99mTc-tetrofosmin dual-phase scintigraphy: a case report.

Authors:  Konstantinos Romanidis; Evangelos Karathanos; Eleni-Aikaterini Nagorni; Alexandra Giatromanolaki; Efthimios Sibridis; Athanassios Zissimopoulos; Theodosia Vogiatzaki; Constantinos Simopoulos; Michael Pitiakoudis
Journal:  BMC Res Notes       Date:  2014-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.